Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 67

Sort by

Sort Order Select

Journal Articles

Treatment selection and functional outcomes in treatment-related acute myeloid leukemia (tAML) and AML with myelodysplasia-related changes (MRC): A multicenter prospective cohort study

Vijaya Bhatt, Christopher Wichman, Joseph Maakaron, Richard Stone, Moataz Ellithi, Michael Haddadin, Lori Maness, Soroush Mortaz-Hedjri, Steven Green, Kah Poh (Melissa) Loh, Sarah Wall, Krishna Gundabolu

Blood (2025) 146 (Supplement 1): 6381.

https://doi.org/10.1182/blood-2025-6381

Published: 2025

Journal Articles

Loss of the Y chromosome defines a biologically distinct subtype of Acute Myeloid Leukemia (AML), associated with decreased inflammatory response patterns, and favorable outcomes in young male patients (pts)

Blood (2025) 146 (Supplement 1): 1723.

https://doi.org/10.1182/blood-2025-1723

Published: 2025

Journal Articles

A randomized, multicenter trial of shorter durations of hypomethylating agents in lower-risk Myelodysplastic Syndromes

Blood (2025) 146 (Supplement 1): 487.

https://doi.org/10.1182/blood-2025-487

Published: 2025

Journal Articles

SWOG 1318: Combination of dasatinib, prednisone, and blinatumomab for older patients with Philadelphia chromosome positive acute lymphoblastic leukemia: longer follow up and predictors of outcomes

Anjali Advani, Anna Moseley, Kristen O'Dwyer, Cecilia Yeung, Olga Sala Torra, Brent Wood, Jae Park, Matthew Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab Atallah, Aaron Gerds, Susan O'Brien, Jane Liesveld, Megan Othus, Mark Litzow, Richard Stone, Jerald Radich, Harry Erba

Blood (2025) 146 (Supplement 1): 3343.

https://doi.org/10.1182/blood-2025-3343

Published: 2025

Journal Articles

Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study

Blood (2025) 146 (Supplement 1): 1001.

https://doi.org/10.1182/blood-2025-1001

Published: 2025

Journal Articles

Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation

Blood (2025) 146 (Supplement 1): 992.

https://doi.org/10.1182/blood-2025-992

Published: 2025

Journal Articles

Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial

Blood (2025) 146 (Supplement 1): 31.

https://doi.org/10.1182/blood-2025-31

Published: 2025

Journal Articles

Trial in progress: A phase I study evaluating the safety of cirtuvivint (CIRT) as monotherapy and in combination with ASTX727 in patients with myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML)

Blood (2025) 146 (Supplement 1): 3431.

https://doi.org/10.1182/blood-2025-3431

Published: 2025

Journal Articles

Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study

Blood (2025) 146 (Supplement 1): 3418.

https://doi.org/10.1182/blood-2025-3418

Published: 2025

Journal Articles

A randomized study of conventional chemotherapy +/- uproleselan in older adults with Acute Myeloid Leukemia eceiving intensive induction chemotherapy (Alliance A041701)

Blood (2025) 146 (Supplement 1): 3415.

https://doi.org/10.1182/blood-2025-3415

Published: 2025

Journal Articles

Somatic mutations predict risk of invasive fungal disease in patients with acute myeloid leukemia treated with intensive induction chemotherapy

Archana Sasi, Victor Kovac, Yiwen Liu, Jessica Little, Ann Woolley, Harrison Tsai, Vincent Ho, Shai Shimony, Eric Winer, Richard Stone, Daniel Deangelo, Marlise Luskin, Lindsey Baden, R. Coleman Lindsley, Rahul Vedula

Blood (2025) 146 (Supplement 1): 5180.

https://doi.org/10.1182/blood-2025-5180

Published: 2025

Journal Articles

A first-in-human study of stx-0712, a CCR2+ cytotoxicity targeting chimera (CyTAC™) in patients with chronic myelomonocytic leukemia (CMML) and Acute Myeloid Leukemia (AML)

Guillermo Montalban-Bravo, Courtney DiNardo, Peter Greenberg, Richard Stone, Eric Padron, David Sallman, Curtis Lachowiez, Jonathan Abbas, Abhishek Mangaonkar, Mrinal Patnaik, Marissa Timothy, Alonzo Martinez, Ewelina Morawa, Brandon Turunen, Philip Vickers, Sergio Santillana

Blood (2025) 146 (Supplement 1): 3874.

https://doi.org/10.1182/blood-2025-3874

Published: 2025

Journal Articles

Venetoclax plus inotuzumab ozogamicin for relapsed and refractory ALL: Results of a phase I trial

Marlise Luskin, Julia Keating, Benjamin Frost, Yael Flamand, Jacqueline Garcia, Richard Stone, Rebecca Leonard, Stella Jaeckle, Chase Weizer, Jessica Lee, Ilene Galinsky, Jeremy Ryan, Eric Winer, Evan Chen, Anthony Letai, Mark Murakami, Daniel Deangelo

Blood (2025) 146 (Supplement 1): 645.

https://doi.org/10.1182/blood-2025-645

Published: 2025

Journal Articles

Increased yield of recurrent structural variants (SVs) in Ph-like B-cell acute lymphoblastic leukemia (B-ALL) using a streamlined clinical whole-genome sequencing (WGS) assay

Blood (2025) 146 (Supplement 1): 1590.

https://doi.org/10.1182/blood-2025-1590

Published: 2025

Journal Articles

Cost-effectiveness of post-transplant gilteritinib maintenance in MRD-positive FLT3-ITD Acute Myeloid Leukemia: A microsimulation model based on the morpho trial

Tina Huang, Gregory Abel, Corey Cutler, Robert Soiffer, Richard Stone, Amar Kelkar

Blood (2025) 146 (Supplement 1): 4436.

https://doi.org/10.1182/blood-2025-4436

Published: 2025

Journal Articles

Prognosis in adults with ph-positive B-ALL in first complete remission without minimal residual disease after blinatumomab consolidation is influenced by minimal residual disease (≥10-4) pre-blinatumomab

Blood (2025) 146 (Supplement 1): 3329.

https://doi.org/10.1182/blood-2025-3329

Published: 2025

Journal Articles

Inotuzumab ozogamicin then blinatumomab for older adults with newly diagnosed, ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Extended follow-up of alliance for clinical trials in oncology A041703 cohort 1 reveals durable remission and survival

Blood (2025) 146 (Supplement 1): 444.

https://doi.org/10.1182/blood-2025-444

Published: 2025

Journal Articles

Tri-partied analyses define clinical outcomes and molecular features of patients (pts) with acute promyelocytic leukemia (APL)

Blood (2025) 146 (Supplement 1): 8183.

https://doi.org/10.1182/blood-2025-8183

Published: 2025

Journal Articles

Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients.

Blood (2025) 146 (Supplement 1): 5279.

https://doi.org/10.1182/blood-2025-5279

Published: 2025

Journal Articles

Impact of therapy delays on outcomes in adults with BCR::ABL1 negative b-lineage acute lymphoblastic leukemia (ALL) in the ECOG-ACRIN E1910 trial randomized to conventional chemotherapy +/- blinatumomab

Blood (2025) 146 (Supplement 1): 1549.

https://doi.org/10.1182/blood-2025-1549

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Treatment selection and functional outcomes in treatment-related acute myeloid leukemia (tAML) and AML with myelodysplasia-related changes (MRC): A multicenter prospective cohort study

Loss of the Y chromosome defines a biologically distinct subtype of Acute Myeloid Leukemia (AML), associated with decreased inflammatory response patterns, and favorable outcomes in young male patients (pts)

A randomized, multicenter trial of shorter durations of hypomethylating agents in lower-risk Myelodysplastic Syndromes

SWOG 1318: Combination of dasatinib, prednisone, and blinatumomab for older patients with Philadelphia chromosome positive acute lymphoblastic leukemia: longer follow up and predictors of outcomes

Revumenib for patients with relapsed or refractory (R/R) KMT2Ar acute leukemia: Outcomes by leukemia type in the phase 2 AUGMENT-101 study

Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation

Genomic determinants of treatment outcome and identification of a new genomic subset of adult acute lymphoblastic leukemia from the ECOG-ACRIN E1910 randomized phase III trial

Trial in progress: A phase I study evaluating the safety of cirtuvivint (CIRT) as monotherapy and in combination with ASTX727 in patients with myelodysplastic syndromes (MDS) and Acute Myeloid Leukemia (AML)

Revumenib for patients with relapsed or refractory (R/R) Nucleophosmin 1–Mutated (NPM1m) Acute Myeloid Leukemia (AML): Outcomes by prior treatment in the phase 2 AUGMENT-101 study

A randomized study of conventional chemotherapy +/- uproleselan in older adults with Acute Myeloid Leukemia eceiving intensive induction chemotherapy (Alliance A041701)

Somatic mutations predict risk of invasive fungal disease in patients with acute myeloid leukemia treated with intensive induction chemotherapy

A first-in-human study of stx-0712, a CCR2+ cytotoxicity targeting chimera (CyTAC™) in patients with chronic myelomonocytic leukemia (CMML) and Acute Myeloid Leukemia (AML)

Venetoclax plus inotuzumab ozogamicin for relapsed and refractory ALL: Results of a phase I trial

Increased yield of recurrent structural variants (SVs) in Ph-like B-cell acute lymphoblastic leukemia (B-ALL) using a streamlined clinical whole-genome sequencing (WGS) assay

Cost-effectiveness of post-transplant gilteritinib maintenance in MRD-positive FLT3-ITD Acute Myeloid Leukemia: A microsimulation model based on the morpho trial

Prognosis in adults with ph-positive B-ALL in first complete remission without minimal residual disease after blinatumomab consolidation is influenced by minimal residual disease (≥10-4) pre-blinatumomab

Inotuzumab ozogamicin then blinatumomab for older adults with newly diagnosed, ph-negative, CD22-positive, B-cell acute lymphoblastic leukemia: Extended follow-up of alliance for clinical trials in oncology A041703 cohort 1 reveals durable remission and survival

Tri-partied analyses define clinical outcomes and molecular features of patients (pts) with acute promyelocytic leukemia (APL)

Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients.

Impact of therapy delays on outcomes in adults with BCR::ABL1 negative b-lineage acute lymphoblastic leukemia (ALL) in the ECOG-ACRIN E1910 trial randomized to conventional chemotherapy +/- blinatumomab

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only